BMYHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $66 — +8.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (52): Analysts have, on balance, been cutting their forecasts.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.1% from it.
Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $65 → $60 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $59 → $53 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Underweight | $40 → $41 |
| 5 Oct 2026 | Leerink Partners | Downgrade | Market Perform | $73 → $59 |
| 5 Oct 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 16 Sept 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 Sept 2026 | Piper Sandler | Reiterates | Overweight | $75 → $82 |
| 10 Sept 2026 | HSBC | Maintains | Hold | — |
| 10 Sept 2026 | HSBC | Maintains | Hold | $60 → $65 |
| 5 Aug 2026 | Argus Research | Upgrade | Buy | — |
| 5 Aug 2026 | Argus Research | Upgrade | Buy | $75 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $66 → $70 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Neutral | $54 → $59 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $72 → $75 |
| 31 July 2026 | Guggenheim | Maintains | Buy | — |
| 31 July 2026 | JP Morgan | Maintains | Overweight | — |
| 31 July 2026 | JP Morgan | Maintains | Overweight | $67 → $73 |
| 31 July 2026 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BMY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Bristol Myers Squibb Co. returned +47.7% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 45% of US stocks
Cheaper than 17% of US stocks
Cheaper than 43% of US stocks
Higher than 42% of US stocks
Higher than 88% of US stocks
Higher than 84% of US stocks
Higher than 89% of US stocks
Higher than 81% of US stocks
Higher than 92% of US stocks
Higher than 93% of US stocks
Higher than 91% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bristol Myers Squibb Co. has a market value of $125.7B and an enterprise value of $159.7B.
Revenue in the twelve months to 30 June 2026: $49.2B. The latest quarter grew 5.7% year on year.
Net income over the same four quarters: $9.3B, a 18.9% net margin.
Diluted earnings per share, trailing twelve months: $4.54.
Free cash flow in the twelve months to 30 June 2026: $11.4B, after $1.3B of capital spending.
Bristol Myers Squibb Co. spent $5.1B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 13.6×; forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 4.14%, paying out 55% of earnings.
Bristol Myers Squibb Co. employs 32,500 people — $1.5M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bristol Myers Squibb and four other drug and biotech companies are preparing to report Q3'26 results, with the sector's earnings taking center stage.
Why it matters — BMY watchers may follow the company's upcoming quarterly results alongside those of its peers.
The headline says Bristol Myers Squibb’s cancer drug doubled progression-free survival time. The excerpt also reports promising results in other solid tumors and places the program within the company’s broader effort to build its growth portfolio.
Why it matters — The reported results and potential across other solid tumors are relevant to BMY watchers tracking development of the company’s growth portfolio.
Bristol Myers Squibb heads into Q3 earnings with growth drugs and higher Eliquis guidance offsetting declines in its legacy portfolio.
Why it matters — Investors following BMY may be watching how growth products and Eliquis guidance balance weakness in older products ahead of the earnings report.
MarketBeat says oncology is heating up alongside GLP-1 drugs, with a potential transformation for some long-standing firms in the sector. The excerpt does not describe a specific cancer breakthrough or its details.
Why it matters — The item frames developments in oncology as potentially consequential for established companies such as Bristol Myers Squibb, but provides no company-specific evidence or details.
The article says Bristol Myers Squibb’s top drugs have lost patent protection and seen declining sales, while a portfolio of growing drugs has performed fairly well recently.
Why it matters — BMY watchers may weigh declining sales from established drugs against recent performance from the company’s growing-drug portfolio.
The 28 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $66, with estimates ranging from $41 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Bristol Myers Squibb Co., 10 rate it a Buy, 17 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 94 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Bristol Myers Squibb Co. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +8.1% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 94 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $80 over the next 12 months.
Bristol Myers Squibb Co. returned +47.7% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions.
The most recent item we track (Zacks Investment Research, 27 Oct 2026): "What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?". Bristol Myers Squibb and four other drug and biotech companies are preparing to report Q3'26 results, with the sector's earnings taking center stage.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com
